MeiraGTx Holdings Plc (MGTX)

MeiraGTx Holdings Plc experienced a stock price increase over the last six months and year, reaching a 52-week high. Weiss Ratings reaffirmed a "Sell" rating for the company. MeiraGTx announced posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress. The CEO sold shares of MeiraGTx stock. MeiraGTx reported its second-quarter 2025 financial and operational results, reporting a loss but exceeding revenue estimates. Raymond James Financial initiated coverage of MeiraGTx with a "strong-buy" rating. MeiraGTx announced the presentation of posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting and reported its first-quarter 2025 financial and operational results. MeiraGTx was granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the treatment of Parkinson's Disease. The CFO & COO also sold shares. MeiraGTx announced positive top-line data from its clinical bridging study of AAV-GAD for the treatment of Parkinson's disease.

There is no readily available information or indication of demand seasonality for MeiraGTx Holdings Plc's products and services, as these are not yet commercialized and subject to market demand fluctuations.

MeiraGTx Holdings Plc is a clinical-stage gene therapy company focused on developing novel treatments for inherited and acquired disorders. The company's pipeline includes gene therapies in various clinical stages for ocular diseases, xerostomia, and neurodegenerative diseases. MeiraGTx also develops a riboswitch platform and cell therapies, and has collaborations with Johnson & Johnson and Hologen Limited.

MeiraGTx Holdings Plc operates in the United States, the United Kingdom, and the European Union. Its headquarters are located in New York, New York, United States.

MeiraGTx's brand reputation has been influenced by positive and potentially negative events. The company received a boost with the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for Parkinson's Disease and analyst coverage initiated by Raymond James with a "strong-buy" rating. However, a "Sell" rating reaffirmed by Weiss Ratings and insider selling by the CEO and CFO & COO could be perceived negatively. The presentation of scientific posters at major conferences contributes positively to its scientific reputation.

MeiraGTx Holdings Plc has a significant institutional ownership presence, with institutions holding a substantial portion of the company's shares. The top five shareholders collectively hold 51% of the business. Major institutional owners include Perceptive Advisors Llc, Sanofi, Johnson & Johnson, Adage Capital Partners Gp, L.l.c., and Prosight Management, LP. Individual ownership includes CEO Alexandria Forbes, and the general public holds a stake in the company.